United States
Include All CSL Behring Country Sites


Albumin (Human) USP 5%/25% Solution

Albumin (Human) 25% is indicated in the emergency treatment of shock due to burns, trauma, operations, and infections; in the treatment of severe injuries; and in other similar conditions where the restoration of blood volume is urgent.
  • Natural plasma protein product
  • Safe and effective therapy for over 50 years

Therapeutic Applications

  • Plasma expansion and replacement - trauma, burns, and shock
  • Conditions where restoration of blood volume is urgent
  • Hypoproteinemia

Safety at the Source

  • Source plasma screening for human immunodeficiency virus (HIV) 1 and 2 and for other vial indicators, including markers for hepatitis B virus and hepatitis C virus
  • 100% of plasma comes from repeat donors, who are routinely tested at the time of each donation

Effective Virus Inactivation

  • Pasteurization (heat treatment in aqueous solution) at 60°C for 10 hours - a demonstrated viral inactivation method that inactivates lipid-enveloped and certain non-lipid-enveloped viruses

Albumin (Human) USP, 5%

NDC Number
Product Description
0053-7670-31 250 mL
0053-7670-32 500 mL

Albumin (Human) USP, 25%

NDC Number
Product Description
0053-7680-32 50 mL
0053-7680-33 100 mL

For intravenous administration
Albumin (Human) USP, 5% and 25%, Albuminar 5 and 25 are indicated in the emergency treatment of shock, burns, severe injuries, and in similar conditions where the restoration of blood volume is urgent. Albuminar-25 is also indicated in hypoproteinemia with or without edema. Albuminar-5 can be used in acutely hypoproteinemic patients, provided sodium is not restricted.

Important Safety Information for Albuminar 5 and Albuminar 25

Albuminar is contraindicated in patients with severe anemia or cardiac failure and in patients with a history of allergic reactions to human albumin.

Reports have been received of anaphylaxis, which may be severe, and hypersensitivity reactions, including urticaria, skin rash, pruritus, edema, erythema, hypotension and bronchospasm. Nausea, vomiting, increased salivation, chills and febrile reactions have also been reported.

Albuminar is derived from human plasma. The risk of transmission of infectious agents, including viruses, and theoretically, the Creutzfeldt-Jakob (CJD) disease agent, cannot be completely eliminated.

Please see the full prescribing information for Albuminar 5.
Please see the full prescribing information Albuminar 25.

Last Updated: 16 October 2013
CRP16-05-0001 05/2016
© 2017 CSL Behring